Kiora Pharmaceuticals Inc

NASDAQ:KPRXUnited States

Tax and Other Receivables 363,706 2,049,965 ------------ Total Current Assets 31,652,637 4,738,031 Non-Current Assets: Property and Equipment, Net 62,609 8,065 Restricted Cash 4,520 4,267 Intangible Assets and In-Process R&D, Net 6,687,100 8,813,850 Operating Lease Assets with Right-of-Use 72,637 106,890 Other Assets 29,851 40,767 ------------ ------------ Total Assets $ 38,509,354 $ 13,711,870 ============ ============ LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts Payable $ 660,415 $ 206,260 Accrued Expenses 1,714,211 1,380,666 Accrued Collaboration Credit 1,119,591 - Operating Lease Liabilities 33,447 47,069 Total Current Liabilities 3,527,664 1,633,995 Non-Current Liabilities: Contingent Consideration 4,133,008 5,128,959 Deferred Tax Liability 779,440 779,440 Operating Lease Liabilities 39,190 59,822 ------------ ------------ Total Non-Current Liabilities 4,951,638 5,968,221 ------------ ------------ Total Liabilities 8,479,302 7,602,216 ------------ ------------ Commitments and Contingencies (Note 8) Stockholders' Equity: Preferred Stock, $0.01 Par Value: 10,000,000 shares authorized; 3,750 designated Series A, 0 shares issued and outstanding; 10,000 designated Series B, 0 shares issued and outstanding; 10,000 shares designated Series C, 0 shares issued and outstanding; 20,000 shares designated Series D, 7 shares issued and outstanding; 1,280 shares designated Series E, 0 shares issued and outstanding; 3,908 shares designated Series F, 420 issued and outstanding at September 30, 2024 and December 31, 2023, respectively 4 4 Common Stock, $0.01 Par Value: 150,000,000 and 50,000,000 shares authorized; 3,000,788 and 856,182 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively 267,679 77,078 Additional Paid-In Capital 168,996,195 153,192,228 Accumulated Deficit (139,158,620) (146,976,855) Accumulated Other Comprehensive Loss (75,206) (182,801) ------------ ------------ Total Stockholders' Equity 30,030,052 6,109,654 ------------ ------------ Total Liabilities and Stockholders' Equity $ 38,509,354 $ 13,711,870 ============ ============ CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (unaudited) Three Months Ended Nine Months Ended September 30, September 30, ------------------------ ------------------------- 2024 2023 2024 2023 ---------- ---------- ---------- ----------- Revenue: Collaboration Revenue $ - $ - $16,000,000 $ - Grant Revenue - - 20,000 - Total Revenue - - 16,020,000 - ---------- ---------- ---------- ----------- Operating Expenses: General and Administrative 1,380,997 1,415,844 4,215,411 3,782,596 Research and Development 1,317,231 1,085,010 3,717,570 2,915,392 In-Process R&D Impairment 2,008,000 1,904,314 2,008,000 1,904,314 Change in Fair Value of Contingent Consideration (1,103,991) 1,513,400 (995,951) 1,865,945 ----------- Total Operating Expenses 3,602,237 5,918,568 8,945,030 10,468,247 ---------- ---------- ---------- Operating Income (Loss) (3,602,237) (5,918,568) 7,074,970 (10,468,247) ---------- ---------- ---------- ----------- Other Income (Expense), Net: Interest Income, Net 248,840 49,912 813,989 128,464 Other Income (Expense), Net (59,929) 105,715 (70,724) 94,493 Total Other Income, Net 188,911 155,627 743,265 222,957 ---------- ---------- ---------- ----------- Net Income (Loss) $(3,413,326) $(5,762,941) $ 7,818,235 $(10,245,290) ========== ========== ========== =========== Deemed Dividends from Warrant Reset Provision - (530,985) - (530,985) ========== ========== ========== =========== Net Loss Attributable to Common Shareholders $(3,413,326) $(6,293,926) $ 7,818,235 $(10,776,275) ========== ========== ========== =========== Net Income (Loss) per Common Share - Basic $ (0.81) $ (7.30) $ 2.08 $ (23.35) Weighted Average Shares Outstanding - Basic 4,214,950 789,656 3,757,467 438,687 ========== ========== ========== =========== Net Income (Loss) per Common Share - Diluted $ (0.81) $ (7.30) $ 1.91 $ (23.35) Weighted Average Shares Outstanding - Diluted 4,214,950 789,656 4,092,880 438,687 ========== ========== ========== =========== Other Comprehensive Income (Loss): Net Income (Loss) $(3,413,326) $(5,762,941) $ 7,818,235 $(10,245,290) Unrealized Gain on Marketable Securities 76,435 - 73,607 - Foreign Currency Translation Adjustments 94,094 (40,310) 33,988 (83,430) Comprehensive Income (Loss) $(3,242,797) $(5,803,251) $ 7,925,830 $(10,328,720) ========== ========== ========== =========== To view the source version of this press release, please visit https://www.newsfilecorp.com/release/67320 To view the source version of this press release, please visit https://www.newsfilecorp.com/release/229204

Total Current Assets 31,652,637 4,738,031 Non-Current Assets: Property and Equipment, Net 62,609 8,065 Restricted Cash 4,520 4,267 Intangible Assets and In-Process R&D, Net 6,687,100 8,813,850 Operating Lease Assets with Right-of-Use 72,637 106,890 Other Assets 29,851 40,767 ------------ ------------ Total Assets $ 38,509,354 $ 13,711,870 ============ ============ LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts Payable $ 660,415 $ 206,260 Accrued Expenses 1,714,211 1,380,666 Accrued Collaboration Credit 1,119,591 - Operating Lease Liabilities 33,447 47,069 Total Current Liabilities 3,527,664 1,633,995 Non-Current Liabilities: Contingent Consideration 4,133,008 5,128,959 Deferred Tax Liability 779,440 779,440 Operating Lease Liabilities 39,190 59,822 ------------ ------------ Total Non-Current Liabilities 4,951,638 5,968,221 ------------ ------------ Total Liabilities 8,479,302 7,602,216 ------------ ------------ Commitments and Contingencies (Note 8) Stockholders' Equity: Preferred Stock, $0.01 Par Value: 10,000,000 shares authorized; 3,750 designated Series A, 0 shares issued and outstanding; 10,000 designated Series B, 0 shares issued and outstanding; 10,000 shares designated Series C, 0 shares issued and outstanding; 20,000 shares designated Series D, 7 shares issued and outstanding; 1,280 shares designated Series E, 0 shares issued and outstanding; 3,908 shares designated Series F, 420 issued and outstanding at September 30, 2024 and December 31, 2023, respectively 4 4 Common Stock, $0.01 Par Value: 150,000,000 and 50,000,000 shares authorized; 3,000,788 and 856,182 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively 267,679 77,078 Additional Paid-In Capital 168,996,195 153,192,228 Accumulated Deficit (139,158,620) (146,976,855) Accumulated Other Comprehensive Loss (75,206) (182,801) ------------ ------------ Total Stockholders' Equity 30,030,052 6,109,654 ------------ ------------ Total Liabilities and Stockholders' Equity $ 38,509,354 $ 13,711,870 ============ ============